Sulfonylurea drugs, commonlyused in type 2 diabetes mellitus treatment, bind to the octamer KATPchannels composed of four pore-forming Kir6.2 and four SUR1 subunitsand increase the probability of insulin release. This evidence concerns the gene KCNJ11 and type 2 diabetes mellitus.